215600.KQ
SillaJen, Inc. [215600.KQ] Stock Forecast
Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
RSI : 000
215600.KQ Stock Summary
Top 10 Correlated ETFs
215600.KQ
Top 10 Correlated Stocks
215600.KQ
In the News
215600.KQ Financial details
Company Rating
-
Market Cap
332.54B
Income
-
Revenue
-
Book val./share
-
Cash/share
-
Dividend
-
Dividend %
-
Employees
-
Optionable
No
Shortable
Yes
Earnings
13 Nov 2023
P/E
0
Forward P/E
-
PEG
-
P/S
-
P/B
-
P/C
-
P/FCF
-
Quick Ratio
-
Current Ratio
-
Debt / Equity
-
LT Debt / Equity
-
-
-
EPS (TTM)
-
EPS next Y
-
EPS next Q
-
EPS this Y
-
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
-
Revenue last 5Y
-
Revenue Q/Q
-
EPS Q/Q
-
-
-
-
-
SMA20
-1.21%
SMA50
3.57%
SMA100
-20.89%
Inst Own
-
Inst Trans
-
ROA
-
ROE
-
ROC
-
Gross Margin
-
Oper. Margin
-
Profit Margin
-
Payout
-
Shs Outstand
70.53M
Shs Float
78.23M
-
-
-
-
Target Price
-
52W Range
3950.0-16550.0
52W High
-70.15%
52W Low
+25.06%
RSI
52
Rel Volume
0.73
Avg Volume
541.55K
Volume
392.81K
Perf Week
-0.9%
Perf Month
2.6%
Perf Quarter
-14.83%
Perf Half Y
-10.99%
-
-
-
-
Beta
0.404536
-
-
Volatility
85.31%, 144.98%
Prev Close
0%
Price
4940
Change
0.61%
Company Profile
- Volume Average 541.55K
- Market Capitalization 332.54B
- CEO Dr. Eun-Sang Moon D.D.S., DDS, M.D.
- Headquarters Seoul,KR
- IPO Date 2016-12-06
-
Website
https://www.sillajen.com 
SillaJen, Inc. engages in the development and commercialization of oncolytic immunotherapy products. The company's lead product is Pexa-Vec, which is in Phase II clinical trial for the treatment of advanced liver cancer. It also develops JX-970 for the treatment of tumor tissues; and JX-900 is a series of modified vaccinia vaccine. The company was founded in 2006 and is headquartered in Seoul, South Korea.
